Dr. Joshi is completed his MD, and MSc and PhD in medical microbiology. Since year 1987 he is in the field of academics, held positions ranging from lecturer through professor at various institutions. He has research experience from the fields of antimicrobial drugs and resistance mechanisms, bacterial pathogen-host interactions and immune responses, infected wound healing, and biofilms and infection control strategies. His current teaching interest includes bacterial infections, antibacterial agents, and vaccines of biodefense interests. Dr. Joshi is a member of American Society of Microbiology (ASM), Infectious Disease Society of America (IDSA), Surgical Infection Society of North America (SISNA), New York Academy of Sciences (NYAS), and holding life memberships of Indian Association of Medical Microbiologist (IAMM), Indian Association of Pathologist and Microbiologist (IAPM) and Society of Biological Chemistry of India (SBC). He is a proud member of ASM’s International Mentoring Program and Minority Mentoring Program.

Novel Antimicrobial and Antibiofilm strategies, Wound infection and Healing, Biofilms, Mechanisms of Bacterial inactivation and ROS, Acinetobacter baumannii Infection, Carbapenem resistance.

Tadashi Shimamoto has completed his PhD at the age of 28 years from Okayama University, Japan and postdoctoral studies from University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School. He is a professor and a vice dean of Graduate School of Biosphere Science, Hiroshima University. He has published more than 60 papers in reputed journals and has been serving as an editorial board member of Microbiology and Immunology.

Microorganisms that cause food poisoning, such as E. coli O157, Salmonella, Vibrio parahaemolyticus, Campylobacter and norovirus.

John Clerici is a founding Principal of Tiber Creek Partners, LLC and a Partner in the government contracts practice at McKenna Long & Aldridge LLP. For over 13 years, John has been at the forefront in the creation of the public health preparedness sector, including helping large pharmaceutical and emerging biotechnology companies develop creative approaches to access non-dilutive capital to fund the development of biotechnology for emerging disease and engineered threats. Since 1999, John has assisted over three dozen companies in obtaining nearly $4 billion in funding for research, development and procurement of public health countermeasures to the Federal government, including the majority of the awards made under Project Bioshield, the U.S. Government’s initiative for preparing the Nation against a bioterrorist attack. In 2005, John played a substantial role in the drafting and passage of the Public Readiness and Emergency Preparedness Act (PREP Act), landmark legislation that provides substantial liability protections for makers and distributors of pandemic, epidemic, and bioterrorism countermeasures. John testified as an expert in support of this legislation on four occasions before the United States Senate Appropriations Committee, HELP Committee, and Judiciary Committee. In 2006, John was instrumental in the passage of legislation creating the Biomedical Advanced Research and Development Authority (BARDA), which builds upon and improves Project BioShield. John’s expertise in the area of public health preparedness has been recognized by leading news outlets such as the Wall Street Journal, Business Week, the Associated Press, the Boston Globe, and The Hill. He has also appeared live on the Fox News Channel as a bioterrorism expert. Prior to joining the firm, John was a judge advocate with the U.S. Air Force where, among other assignments, he advised the Air Force Research Laboratory on the procurement of technology from research institutions throughout the United States, Europe and Asia. John has appeared as a military law analyst for the Fox News Channel and MSNBC before national audiences. John earned his Juris Doctor from the University of North Carolina at Chapel Hill. He did his undergraduate work at the Catholic University of America, graduating summa cum laude.

Public health Pharmaceutical and emerging biotechnology

Glenn is a Senior Partner at TranScrip Partners USA. He is trained in medical microbiology and infectious diseases and has over 25 years of pharmaceutical industry experience in various areas including clinical research, commercialization, scientific communications including publication planning, strategic drug development, life cycle management and global launch programs. Glenn has been instrumental in the development of ciprofloxacin and moxifloxacin as well as other drugs in the Bayer portfolio for whom he worked for 15 years. After leaving Bayer he worked as a consultant microbiologist and later joined Oscient, during which time he was involved in the commercialization and launch of gemifloxacin (Factive) in the US as well as co-marketing and business development deals globally. In 2006 he joined Replidyne as Executive Director of Scientific Affairs and worked on the company’s anti-infective portfolio, including faropenem. In 2008 Glenn became the Head of Medical Affairs at ViroPharma where he oversaw educational, publication and other related activities for Vancocin, maribavir and Cinryze. He later worked for Optimer Pharmaceuticals as Senior Vice President of Medical Affairs and built a team to support the launch of fidaxomicin (Dificid) which has been one of the most successful antibiotic launches ever. Glenn is a member of the Scientific Steering Committee for the GTCBio Annual Summit on Anti-infective Partnering as well as the Anaerobe Society. He is also Chair of the ACCP Chest Infection Network and a member of the ACCP Executive Council of Networks. In 2009 Glenn was honored by the American College of Chest Physicians with the Alfred Soffer Award for contributions to the College. He has published over 140 peer-reviewed manuscripts, presented >270 scientific posters, wrote 5 book chapters and is editing a upcoming e-book on Clostridium difficile. Glenn is on several journal Editorial Advisory Boards including the Lancet Infectious Disease and F1000.

strategic drug development life cycle management